CSTONE PHARMA-B: DATE OF BOARD MEETING

HKEXMar 17 12:00 · Announcements

All the way up! The Innovative Drugs Sector in Hong Kong stocks surged collectively, with multiple stocks doubling this year. Who is reshaping the valuation?

The rise in the Hong Kong stock market's Innovative Drugs Sector continues. Market analysts point out that this wave of Innovative Drugs momentum benefits from a combination of factors including market sentiment, policy, and the realization of the companies' own commercial value.

Securities TimesMar 13 09:50

CSTONE PHARMA-B (02616.HK): Advancing towards Pipeline 2.0 with significant potential for ROR1ADC.

Abstract: CStone Pharmaceuticals is an innovation-driven Biomedical company focused on the research and development of anti-tumor drugs. As of February 2025, the company has successfully launched 4 Innovative Drugs, received approval for 16 new drug marketing applications (NDA), and 9.

TianfengMar 11 07:47

Express News | Tianfeng Securities Co., Ltd. gave a buy rating to Cornerstone Pharmaceuticals with an initial Target Price of 6.75 Hong Kong dollars.

BreakingsMar 10 21:17

CSTONE PHARMA-B (02616.HK) submitted a clinical trial application in Australia for CS5001 (ROR1 ADC) in combination with standard treatment for first-line DLBCL.

On March 6, Glorious Finance reported that CSTONE PHARMA-B (02616.HK) announced it has successfully submitted an application for an Ib phase clinical trial in Australia for CS5001 (ROR1 ADC) combined with standard treatment for frontline diffuse large B-cell lymphoma (DLBCL). In addition, a global multicenter clinical trial of CS5001 as a monotherapy and in combination with PD-L1 monoclonal antibody for advanced solid tumors is also ongoing. This Ib phase clinical trial further expands on the data from CS5001 monotherapy treatment for refractory and indolent advanced lymphoma, aiming to explore ROR1 ADC in depth.

Gelonghui FinanceMar 6 08:05

CStone Pharmaceuticals Carries Out First Dosing in Multi-Cancer Drug Trial

MT NewswiresMar 4 13:43